Clinically measurable response requires 3 to 4 months 2, 6, 10, 14, 16. However GnRH agonists are used primarily mainly as adjuvant therapy for residual or recurrent tumors among patients who are poor candidates for surgery or for those who refuse surgery but who test positively for estrogen and progestin receptors, independently of the strength of that positivity 2, 6, 7. In the absence of sufficient studies hormone therapy cannot replace surgery.
Los agonistas de GnRH, sin embargo, son adoptados principalmente como una terapia adyuvante ante tumores recurrentes o residuales que son ER y PR estrógeno y progestágenos receptores positivos independiente de la fuerza de su positividad, aquellos pacientes que sean pobres candidatos a cirugía, en quienes se prevea una cirugía mutilante o rechacen la opción quirúrgica 2, 6, 7.